Game-Changing Health Management Platform Ready for IBD Patients

As telemedicine continues to receive favorable reviews from healthcare professionals and patients, SonarMD, LLC recently released its SonarMD platform for securely engaging, monitoring, and managing patients with chronic gastrointestinal diseases.

As telemedicine continues to receive favorable reviews from healthcare professionals and patients, SonarMD, LLC recently released its SonarMD platform for securely engaging, monitoring, and managing patients with chronic gastrointestinal diseases.

Lawrence Kosinski, MD, MBA, managing partner of the Illinois Gastroenterology Group (ICG), developed the cloud-based algorithmic process to provide physicians with better channels for closely monitoring their patients’ progress between scheduled visits.

In line with nationally recognized evidence-based guidelines, SonarMD applies a Patient Reported Outcomes score to electronic health assessment survey submission. This, in turn, notifies the physicians to any potentially negative dip in the patients’ conditions — resulting in possible early intervention, fewer hospitalizations, and improved overall patient care.

Tracey Powell, SonarMD, CEO, commented, “While providing a powerful support and decision-making system for current patients and the physicians who care for them, SonarMD data will, over time, be instrumental in the creation of new and better care pathways for future patients and their care providers.”

Patients with Crohn’s Disease at the ICG were the first group to receive the first release of SonarMD Platform. Kosinski believed, “inflammatory bowel disease (IBD) is associated with a high rate of preventable hospital admissions due to delay in outpatient treatment. IBD is painful and life altering for patients and costly for prayers. The purpose of SonarMD is to empower patients in their own care and improve it, as well as prevent costly hospitalizations.

According to Kosinski, once fully implemented at ICG, the SonarMD Platform will be included in a national roll-out — first to other IBD specialized practices, but gradually to other chronic disease populations as well.